Mark Tim­ney, the ex-Pur­due Phar­ma CEO named in dozens of law­suits against the Oxy­Con­tin mak­er, stands to earn over $85 mil­lion in No­var­tis’s $9.7 bil­lion buy­out of the Med­i­cines Com­pa­ny.

Tim­ney joined the Med­i­cines Com­pa­ny as CEO in De­cem­ber, af­ter four years helm­ing the com­pa­ny broad­ly con­sid­ered to be at the heart of the opi­oid abuse cri­sis. SEC fil­ings from the time of his hire show he agreed to pur­chase $500,000 worth of stock at the time and was al­so grant­ed one mil­lion per­for­mance and time-vest­ed stock op­tions.

Every em­ploy­ee stock op­tion will vest per the agree­ment and No­var­tis is of­fer­ing $85 per share. With 30,000 shares he owned as of a Sep­tem­ber fil­ing and pur­chased for $21.60 a share, Tim­ney could take home a lit­tle over $87 mil­lion.

A spokesper­son for the Med­i­cines Com­pa­ny de­clined to com­ment on ex­ec­u­tive com­pen­sa­tion.

Tim­ney re­mains a named de­fen­dant in over 30 on­go­ing law­suits against Pur­due Phar­ma, the drug gi­ant ac­cused of mis­lead­ing doc­tors on the ad­dic­tive­ness of its best-sell­ing drug. Tim­ney, the Con­necti­cut At­tor­ney Gen­er­al’s com­plaint al­leges, di­rect­ed his sales­force to tout the sup­posed abuse-de­ter­rent tech­nol­o­gy in Oxy­Con­tin even as he gave in­ter­nal pre­sen­ta­tions ac­knowl­edg­ing that the tech­nol­o­gy was un­like­ly to work and pa­tients would con­tin­ue to be­come ad­dict­ed.

Tim­ney and his pre­de­ces­sor John Stew­art “par­tic­i­pat­ed di­rect­ly in Pur­due’s un­fair and de­cep­tive acts and prac­tices al­leged in this com­plaint,” the com­plaint al­leges. “They had the au­thor­i­ty to con­trol Pur­due’s busi­ness prac­tices, in­clud­ing com­plete over­sight and con­trol over Pur­due’s cor­po­rate poli­cies and ac­tiv­i­ties. They were ac­tive­ly in­volved in Pur­due’s busi­ness af­fairs and ac­tive­ly par­tic­i­pat­ed in the mak­ing of com­pa­ny pol­i­cy. They knew of the un­fair and de­cep­tive acts and prac­tices al­leged here­in, and their ac­tions and in­ac­tions re­sult­ed in the mis­con­duct.”

The Mass­a­chu­sets com­plaint al­leges “John Stew­art, Mark Tim­ney, and Craig Lan­dau each di­rect­ed Pur­due’s de­cep­tion as CEO of Pur­due Phar­ma.”

Med­i­cines Com­pa­ny spokesman Michael Blash de­fend­ed Tim­ney’s re­sume and work for the biotech in an email to End­points News: “Mark is an ac­com­plished and com­mit­ted health­care leader whose lead­er­ship has served the com­pa­ny well dur­ing this im­por­tant strate­gic phase.”

Steve Holtzman was awoken by a 1 a.m. call from a doctor at Duke University asking if he could put some pigs on a plane and fly them from Ohio to North Carolina that day. A motorcyclist had gotten into a horrific crash, the doctor explained. He believed the pigs’ livers, sutured onto the patient’s skin like an external filter, might be able to tide the young man over until a donor liver became available.

Back in March, Merck and Gilead agreed to a partnership to challenge GlaxoSmithKline on long-acting HIV meds — by combining one drug from both Merck and Gilead that had shown potential. While Gilead brought its capsid inhibitor lenacapavir, Merck brought islatravir into the deal — a small molecule that the pharma acquired in 2012 from a small Japanese firm.

While that partnership is ongoing, islatravir is coming out of 2 Phase III pivotal trials with back-to-back successes and plans to beat a quick advance to the FDA.

More than 4 years after little Erytech inflated some rare passion for its stock with upbeat Phase IIb data for their lead drug in pancreatic cancer, they’ve let the air out of the party balloons.

The transatlantic biotech $ERYP put the word out Monday morning that its drug eryaspase flopped in a Phase III pivotal for second line metastatic pancreatic cancer, slamming its stock, which plunged more than 30%.